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Abstract
Background: Xian-Fang-Huo-Ming-Yin (XFHM), a traditional herbal formula, has been used to treat sores and
carbuncles for hundreds of years in Asia. Nowadays, its clinical effects in treatment of rheumatoid arthritis (RA) have
been validated. In this study, we want to study its possible molecular mechanisms of regulating the differentiation of
lymphocytes and production of pro-inflammatory cytokines in collagen-induced arthritis (CIA) mice for RA treatment.
Methods: A high performance liquid chromatography-electrospray ionization/mass spectrometer (HPLC-ESI/MSn)
system was used to analyze the constituents of XFHM granules. An arthritics mouse model was induced by collagen
and leflunomide (LEF) was used as a positive control medicine. Pathological changes at the metatarsophalangeal joint
were studied through Safranin O and immunohistochemical staining. The differentiation of T, B and NK cells was
examined by flow cytometry and pro-inflammatory cytokines were assayed using an Inflammation Antibody Array
assay. The expression of key molecules of the nuclear factor κB (NF-κB) and Janus kinase/signal transducers and
activators of transcription (JAK/STAT) signaling pathways in spleen were studied by western-blot analysis.
Results: In our study. 21 different dominant chemical constituents were identified in XFHM. Treatment with XFHM
suppressed the pathological changes in arthrosis of CIA. Additionally, XFHM down-regulated the proliferation and
differentiation of CD3+ T cells and CD3−CD19+ B cells significantly. However, XFHM had no significant effect on CD3
−NK1.1+ NK cells. Further study showed that the production of pro-inflammatory cytokines had been suppressed by
inhibiting the activation of NF-κB and JAK/STAT signaling.
Conclusions: XFHM can regulate and maintain the immunologic balance of lymphocytic immunity and inhibit the
production of pro-inflammatory cytokines, thus suppressing the pathological changes of RA. Therefore, XFHM may be
used as an application of traditional medicine against RA in modern complementary and alternative therapeutics.
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Background
Rheumatoid arthritis (RA) is a chronic inflammatory auto-
immune disease with articular and systemic effects [1].
The pathogenesis of RA is not fully understood. Various
inflammatory cells, including innate immune cells (mast
cells, macrophages, dendritic cells and natural killer (NK)
cells) and adaptive immune cells (T and B cells), are acti-
vated in RA joints, contributing to the pathogenesis of
RA. Endothelial cells and fibroblast-like synoviocytes also
participate in the disease progress of RA [2]. These cells
constitute the synovial lining layer and participate in an
inflammatory cascade, eventually inducing the destruction
of cartilage and bone [3].
It is well known that RA is a T-cell dependent auto-
immune disease. CD3+ T cells, cooperating with the in-
flammatory cytokines excreted by T cells, induce synovial
inflammation, further leading to the destruction of articu-
lar cartilage [4]. B cells also contribute to RA pathogenesis
by antigen presentation and inflammatory cytokines pro-
duction [5]. Cell-cell interaction of T and B cells promote
the excretion of cytokines and chemokines, reinforce the
interaction of the feedback loop among T cells, macro-
phages and B cells, and maintain the progress of synovial
inflammation and destruction of cartilage and bone [6].
NK cells have been reported to play an important role in
the tissue pathology of RA [7]. NK cells have a disease-
promoting function on RA tissue. A subset of NK cells
expanding in inflamed synovium has been demonstrated,
after which the production of interferon (IFN) γ is induced
to a significant degree [8, 9]. NK cells cooperating with
other cell types by cytokines and chemokines may be a po-
tential risk for RA pathogenesis.
Pro-inflammatory cytokines play key roles in the patho-
physiology of RA. It is well established that tumor necrosis
factor (TNF) α and interleukin (IL)-6 play the dominant
roles [10, 11]. IL-1, IL-17 and IFNγ also contribute to the
process of RA [10, 12]. These pro-inflammatory cytokines
mediate cell migration and cause synovial inflammation,
which eventually result in cartilage and bone destruction.
Nuclear factor κB (NF-κB) plays a central role in the dif-
ferentiation, activation and survival of mammalian cells,
contributing to RA in multiple ways. It can induce the
production of pro-inflammatory cytokines and other me-
diators of inflammation, thereby accelerating the progress
of RA pathology [13]. In addition, the Janus kinase/signal
transducers and activators of transcription (JAK/STAT)
signaling cascade activated by IL-6 participates in the
pathogenesis of RA [14].
Xian-Fang-Huo-Ming-Yin (XFHM), is a formula de-
scribed in the ancient Chinese herbal treatise Jiaozhu Furen
Liangfang, which was compiled by Xue Ji during the Ming
dynasty of ancient China. This typical traditional Chinese
medical (TCM) formula has been used for hundreds of
years. It is used to treat many diseases such as sores and
carbuncles. We used an optimized formula of XFHM
(other used name Lijie capsule) as a TCM treatment for RA
and found a good therapeutic effect [15]. Additionally, pre-
vious studies from our laboratory suggested that the opti-
mized formula of XFHM has inhibitory effects on apoptosis
of lymphocytes in rats with adjuvant arthritis [16]. In previ-
ous studies, we discovered that chlorogenic acid and Luteo-
lin, the main components of Caulis Lonicerae Japonicae
(the monarch drug in XFHM), can inhibit the inflammatory
proliferation of rat synovial cells induced by IL-1β [17] and
IL-6 [18]. In addition, several studies have indicated that
both the crude herbs and the active ingredients of these
herbs have beneficial effects on RA. These effective proper-
ties include anti-inflammation [19, 20], anti-oxidation [21],
anti-proliferation [22], promoting bone metabolism[23] and
stimulating osteoblasts proliferation [24]. Therefore, we
suggest that XFHM has inhibitory effects on the inflamma-
tory proliferation of synoviocytes and the subsequent de-
struction of cartilage and bone.
In this study, full ingredient granules of XFHM were used
as the treatment drug. The quantity control of the full com-
position granules of XFHM was assayed using the infrared
fingerprint spectrum (IRFP) technique [25]. High perform-
ance liquid chromatography-electrospray ionization/mass
spectrometer (HPLC-ESI/MSn) analysis was used to
characterize the phytochemicals of XFHM. Leflunomide
(LEF), a disease-modifying anti-rheumatic drug (DMARD),
was used as a positive control medicine. Collagen-induced
arthritis (CIA) in DBA1/J mice induced by immunization
with bovine CII in freund’s complete adjuvant (CFA) was
used as an animal model. This investigation was under-
taken to determine the regulatory effects of XFHM on the
proliferation and differentiation of T, B, and NK cells, and
the production of pro-inflammatory cytokines in CIA mice.
Methods
Herb materials and preparation of XFHM
The modified formula of XFHM was composed of 12 medi-
cinal herbs. Full composition granules of the 12 herbs were
provided by Beijing Tcmages Pharmaceutical Co. LTD
(Beijing, China). Quality control of the XFHM granules was
executed through infrared spectrum fingerprint (IFRP). The
IRFP graph is shown in Additional file 1: Figure S1. The
constitution ratio of 12 herbs was Atractylodes lancea (2),
Ligusticum chuanxiong Hort (2), Paeonia veitchii Lynch (2),
Tail of Radix Angelicae sinensis (2), Angelica dahurica (3),
Radix Saposhnikoviae (3), Boswellia carteri Birdw (1), Com-
miphora myrrha (1), Astragalus membranaceus (8), Caulis
Lonicerae Japonicae (6), Gentiana macrophylla Pall (3) and
Rehmannia glutinosa Libosch (3).
HPLC-ESI/MSn analysis
HPLC-ESI/MSn analysis was performed on a Shimadzu
20LC (Kyoto, Japan) coupled to a diode array detector and
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TripleTOF 4600+ CDS mass spectrometer (AB Sciex, MA,
USA). The chromatographic separations were carried out
on an Agilent Poroshell C18 (2.1 mm× 100 mm, 2.7 μm).
The mobile phase consisted of a combination of A (0.5‰
formic acid and 2 mM acetic acid) and B (0.5‰ formic acid
and 2 mM acetic acid in acetonitrile methyl alcohol (1:1))
with a linear gradient, 0–10 min (5–20%, B), 10–22 min
(20–95%, B). The flow rate was 0.4 mL/min, the sample in-
jection volume was 5 μl and the column and sample
temperature were BOTH 40 °C. The diode array detector
(DAD) was set at 200, 220, 250 and 280 nm for the real-
time monitoring of the peak intensity. Mass spectra were
simultaneously acquired using electrospray ionization in
the positive and negative ionization (POS and NEG) modes
at fragmentation voltages (40 Psi) over the range of m/z
50–1250. The data was acquired with IDA (information
dependent acquisition) method and analyzed by Peak View
Software™ 2.2 (SCIEX, Foster City, CA, USA).
CIA induction in DAB1/J mice
DBA1/J male mice (7 to 8 weeks old) purchased from HFK
Bioscience Co. Ltd. (Beijing, China) were immunized intra-
dermally at the base of the tail with 150 μg of bovine type
II collagen (CII) (Sigma, St. Louis, MO, USA) emulsified
with an equal volume of complete Freund’s adjuvant (CFA)
(Sigma, St. Louis, MO, USA). The DBA1/J mice were
boosted 21 days after immunization by intradermal injec-
tion with 150 μg of CII emulsified with incomplete Freund’s
adjuvant (IFA). Animal care and use were in accordance
with institutional guidelines, and all animal experiments
were approved by the Institutional Animal Care and Use
Committee of the National Institute of state Scientific and
Technological Commission.
Drug treatment
Mice were randomly divided into 4 groups as follows (n
= 6 per group): normal group, fed with control diet and
orally administrated sterile saline; model group, fed same
as the normal group; LEF (Batch No. 130126, Cinkate
Corporation, Beijing, China) group, LEF, fed with control
diet and orally daily administrated 2 mg/kg LEF daily for
28 days; and XFHM group, fed with control diet and or-
ally administrated 5.3 g/kg XFHM daily for 28 days.
Drug treatment started from the first day after booster
immunization. Mice were treated with 0.1 mL drug solu-
tion by gavage every day. Mice were sacrificed on day 29
after treatment. Mice were anesthetized by isoflurane
anesthesia (2–3% isoflurane with oxygen supply). The
sample size calculation was based on the basic principles
of hypothetical randomized controlled trial [26]. Periph-
eral blood (PB) was obtained by removing the eyeballs
prior to sacrifice during anesthesia, and the left legs and
hind paws and spleens were removed after sacrifice.
Arthritic severity scores of CIA
Arthritic severity scores of CIA were monitored every
7 days after booster immunization. The arthritic severity
scores for paws were used to reflect the severity of arth-
ritis. Scores were classified as 0 (normal joints), 1 (swelling
in 1 digit or joint inflammation), 2 (swelling in 2 or 3
digits or slight paw swelling), 3 (swelling in more than 4
digits and moderate swelling in the entire paw), 4 (severe
swelling and deformation of the paw). Each paw was
graded, and the four scores were added together so that
the maximum possible score was 16 per mouse [27, 28].
Safranin O and immunohistochemical staining
The left hind legs and paws of the mice were removed,
fixed with 4% paraformaldehyde in PBS, decalcified for
10 days with EDTA, embedded in paraffin, and sectioned
at 5μm thickness. For Safranin O staining, sections were
placed in hematoxylin for 2 min and then washed in water
for 5 min. the sections were then placed in 0.1% Safranin
O solution for a further 2 min and washed again in water
for 30 s. Finally, the sections were passed through a series
of industrial methylated spirit concentrations (70 to 100%)
for 2 min at each concentration. The sections were then
clarified in xylene for 2 min. the sections were then
viewed, and images were taken using a light microscope.
Immunohistochemical staining for IL-1β and IL-17 was
performed. After the sections were de-paraffinized, rehy-
drated and washed, the sections were then antigen-
retrieved with pepsin and incubated with 0.3% hydrogen
peroxidase for 20 min to block endogenous peroxidase ac-
tivity, followed by processing with serum for 30 min to
block non-specific ligations. The sections were then
treated with rabbit anti-IL-1β and IL-17 (1:100, Santa
Cruz Biotechnology, CA, USA) primary antibodies over-
night at 4 °C, washed and incubated with reagents from
an immunohistochemical kit (Zhongshan Biotechnology
Ltd, Beijing, China) in compliance with the manufacturer’s
instructions and visualized with 3,3-diaminobenzidine tet-
rahydrochloride (DAB). Finally, the sections were counter-
stained with hematoxylin. The sections were then viewed
and images were taken using a light microscope. The IOD
(integrated optical density) analysis was performed by
Image-Pro Plus 6.0 (Media Cybernetics, MD, USA). Three
samples in each group were reviewed five sections. The
histological changes were assessed by two experienced pa-
thologists who were blind to the treatment.
Flow cytometry (FACS) analysis
PB (0.2 mL) and half of the spleen were harvested after the
mice anesthetized. Single-cell suspensions from CIA
mouse spleens and PB were isolated. For surface marker
staining, fluorescence conjugated anti-mouse-CD3e-PE,
anti-mouse-CD19-PE-Cyanine7 and anti-mouse- NK1.1-
FITC antibodies (CST, Boston, MA, USA) were used.
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FACS was performed using a FACS Calibur cytometer and
analyzed using the CellQuest software (Beckman Coulter,
Fullerton, CA, USA).
Inflammation antibody array assay
PB (0.6 mL) of the mice was harvested. Sera were sepa-
rated through centrifugation at 1000 g/25 min. The levels
of inflammatory antibodies in sera were detected by Ray-
Biotech® Mouse Inflammation Antibody Array 1 (AAM-
INF-G1, Ray Biotech Inc. Norcross, GA, USA), according
to the manufacturer’s instructions. Briefly, 50 μL of serum
was used in inflammation cytokines assays. The standard
array matrix consisted of an 11 × 8 dot grid on a 20 mm×
30 mm nitrocellulose membrane with 40 unique capture
antibodies. The array kit included a biotinylated-antibody
solution and chemiluminescent substrate. The cytokine
array membrane was incubated with 50 μL of serum for
two hours, and the membrane was then washed three
times with washing buffer 1 for 5 min each, followed by
washing buffer II for 5 min each. Cytokines were detected
using the cytokine antibody for one hour, followed by
HRP-labeled streptavidin incubation for one hour. Fluor-
escence signals were scanned by a Microarray Scanner
(GenePix 4000B, Axon, SFO, CO, USA) at 532 nm. Data
acquisition and analysis were executed using the data ana-
lysis software AAM-INF-G1.
Western blot analysis
The other half of the spleens of CIA mouse was homog-
enized in 1 ml of a lysis buffer (Sigma, CA, USA). The
extracts were cleared by spinning at 10,000 g at 4 °C for
15 min, and then diluted with the lysis buffer to achieve
approximately 2 mg/ml protein concentration. Protein
samples were separated on 10% sodium dodecyl sulfate
(SDS)-polyacrylamide gel electrophoresis (PAGE) and
transferred onto nitrocellulose membranes (Amersham
Pharmacia Biotech, Uppsala, Sweden). The membranes
were incubated with primary antibodies, including anti-
NF-κB kinase inhibitor (IKK)α/β, anti-NF-κB p50, anti-
glycoprotein (gp)-130, anti-JAK1 and anti-STAT3 rabbit
anti-mouse monoclonal antibodies (CST, Boston, MA,
USA), and were then incubated with horseradish
peroxidase-conjugated secondary antibody. All immuno-
reactive proteins were visualized with SuperSignals west
Pico Chemiluminescent Substrate (Thermo Scientific,
Rockford, IL, USA). Densitometry plots showing the ex-
pression of proteins were normalized to glyceraldehyde
3 - phosphate dehydrogenase (GAPDH) and expressed
as fold relative to the levels in mice of the normal group.
Statistical analysis
All data are presented as the means ± standard deviation
(S.D.). The statistical analyses were performed using
SPSS13.0 (SPSS Inc., Chicago, IL, USA). One-way analysis
Fig. 1 HPLC-ESI/MSn total ion chromatograms of XFHM processed by different methods. a The negative base peak MS spectrum, b the positive base
peak MS spectrum
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of variance (ANOVA) followed by the Tukey-Kramer test
for multiple comparisons were used to compare the groups.
P < 0.05 was considered to indicate statistical significance.
Results
Identification of chemical constituents in XFHM by HPLC-
ESI/MSn
Representative liquid chromatography-mass spectrometry
chromatograms are shown in Fig. 1. In the HPLC-ESI/
MSn experiment, both negative (Fig. 1a) and positive
(Fig. 1b) modes were tried. Twenty-one constituents were
identified by comparing the retention time with IDA
method. The identified compounds are shown in Table 1.
Effect of XFHM on histopathological changes in
metatarsophalangeal joints of CIA mice
Mice treated with XFHM exhibited significant reduc-
tions in severity of CIA (Fig. 2a). On day 21 after booster
immunization, the mean arthritic severity score for the
group treated with XFHM was 6.17 ± 0.75, as opposed
to 10.50 ± 1.05 for the model group. The XFHM treat-
ment reduced arthritic severity scores at 0–28 days after
booster injection in the CIA mice.
A decrease in Safranin O staining of the growth plates
in CIA mice was evident prior to any morphological
changes in the chondrocytes [29]. There were also differ-
ences in growth plates Safranin O staining among the
groups (Fig. 2b). The intensity of Safranin O staining was
significantly lower in the CIA mice relative to normal
mice. After treatment with LEF and XFHM, the intensity
of staining increased. Immunohistochemical detection and
localization showed that IL-1β and IL-17 were expressed
in the synovium, pannus and chondrocytes. As showed in
Fig. 2c and d, significant differences were observed be-
tween normal and CIA mice. The abnormal expression of
IL-1β and IL-17 decreased significantly with the LEF and
XFHM treatments.
Intervention in the differentiation of T, B and NK cells in
CIA mice
XFHM and LEF both could decrease the high levels of
CD3+ T cells in PB of CIA mice (Fig. 3a and b) (P =
0.025 or 0.001). In addition, XFHM decreased the level
of CD3+ T cells in spleen (Fig. 3c and d) (P = 0.018). The
percentages of CD3−CD19+ B cells in PB (Fig. 3) and
CD3−NK1.1+ NK cells in PB and spleen (Fig. 4) of CIA
mice were increased significantly (P ≈ 0.001, 0.001 or
0.001). The abnormal rising of CD3−CD19+ B cells in PB
was inhibited significantly after treatment with XFHM
and LEF (Fig. 4) (P ≈ 0.001 or 0.001). Moreover, LEF
Table 1 Chemical components identified from XFHM by HPLC-ESI/MSn
No. TR (min) [M + H]/[M-H] (m/z) Fragments (m/z) Formula Identification
1 7.03 /167.03 /152.0,132.0 C8H8O4 Vanillic acid
2 7.21 375.13 321.1,169.1 C16H24O10 Loganic acid
3 7.73 /179.03 /135.0 C9H8O4 Caffeic acid
4 8.03 /353.09 /173.0,135.0 C16H18O9 Chlorogenic acid
5 9.63 357.12 195.1,121.1 C16H20O9 Gentiopicroside
6 10.16 481.17 179.1,151.1 C23H28O11 Paeoniflorin
7 10.81 391.16 179.1,149.0 C17H26O10 Loganin
8 11.35 179.07 77.0,105.1 C10H10O3 Methyl 4-hydroxycinnamate
9 12.28 /563.14 /383.1,473.1 C26H28O14 Apiin
10 12.79 469.17 307.1,261.1 C22H28O11 Prim-O-glucosylcimifugin
11 13.27 /631.17 /491.1,271.0 C30H32O15 Galloylpaeoniflorin
12 13.44 307.12 259.1,235.1 C16H18O6 Cimifugin
13 14.03 /623.20 /461.2,161.0 C29H36O15 Acteoside
14 15.01 431.13 267.07 252.04 C22H22O9 Ononin
15 15.39 463.16 301.1,167.1 C23H26O10 Lactiflorin
16 15.81 285.06/283.06 220.1, 225.1
/268.0,211.0
C16H12O5 Wogonin
17 16.14 461.11 270.1,285.1 C22H20O11 Wogonoside
18 16.2 /271.06 /151.0,119.1 C15H12O5 Naringenin
19 17.55 269.07/267.07 197.1, 226.1
/252.0,223.0
C16H12O4 Formononetin
20 19.13 /269.08 /254.1,210.1 C16H14O4 Isoimperatorin
21 20.00 /829.46 /621.40,651.41 C41H68O14 Astragaloside IV
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inhibited the proliferation of CD3−NK1.1+ NK cells in
PB and spleen (P = 0.001 or 0.029). However, XFHM had
no significant regulatory effect on NK cells (Fig. 5).
Effect of XFHM on the production of pro-inflammatory
and anti-inflammatory cytokines
Next, we detected 40 types of pro-inflammatory cytokines
in serum by Inflammation Antibody Array analysis. The
results for 9 cytokines associated with RA are shown in
Fig. 6. The levels of predominant pro-inflammatory cyto-
kines contributing to the pathogenesis of RA, including
IL-1β, TNFα, IFNγ, IL-6 and IL-17, were increased
significantly in CIA mice. The production of those cyto-
kines was restrained to different extent after treatment
with LEF or XFHM. Amazingly, significant inhibitory ef-
fects appeared on the productions of IL-1β, TNFα, IFNγ
and IL-6. However, there were no positive regulatory ef-
fects on IL-4, IL-10 or IL-13 from XFHM treatment.
Inhibition of the activation of the NF-κB and JAK/STAT
signaling pathways by XFHM treatment
We also performed western-blotting to test the produc-
tion of key protein molecules of the NF-κB and JAK/
STAT signaling pathways in spleen. The production of
Fig. 2 a Arthritic severity scores of CIA were monitored every 7 days after booster immunization. **P < 0.01 indicates model group vs. normal group;
#P < 0.05 and ##P < 0.01 indicate treatment groups vs. model group. b Safranin O staining of the articular cartilage. The arrows indicate Safranin O
staining. c Immunohistochemical staining for IL-1β. The arrows indicate the location of IL-1β. d Immunohistochemistry staining for IL-17. The arrows
indicate the location of IL-17. The results of integrated optical density (IOD) analysis are presented in the bar charts. Data are presented as the means
± S.D. (n = 3). The specimens were observed and photographed under a light microscope (Leica, DM RXA2) at magnification of 200 ×; a normal group,
b model group, c group treated with LEF, d group treated with XFHM. The scale bar corresponds to 60 μm throughout
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IKKα/β, NF-κB p50 (NF-κB signaling) and gp130, JAK1,
and STAT3 (JAK/STAT signaling) proteins in CIA mice
were increased notably, as compared with mice in the
normal group (P ≈ 0.001, 0.008, 0.001, 0.001 or 0.001).
As shown in Figs. 7 and 8, the abnormally higher levels
of those molecules decreased significantly after LEF or
XFHM treatment. These data suggest that XFHM exerts
inhibitory effects on the production of pro-inflammatory
cytokines by suppressing the activation of the NF-κB
and JAK/STAT signaling pathways.
Discussion
In TCM, combinatory therapeutic strategies according
to patient symptoms are often applied to various types
of diseases [30]. The combinations of herbs form multi-
herbal formulae for diseases treatment. Treatment by
such formulae has been verified scientifically for treat-
ment on several diseases as an effective complementary
or alternative therapy [31]. In this study, we focused on
the therapeutic efficacy of a traditional herbal formula
XFHM on RA, XFHM, and the mechanisms by which it
regulates both the differentiation of T, B and NK cells
and the production of pro-inflammatory cytokines. Sup-
pressing effects on NF-κB and JAK/STAT signaling path-
ways were also detected.
As described previously, the formula of XFHM is con-
sists of 12 medicinal herbs. It has been suggested that
these herbs or the active ingredients in these herbs offer
beneficial effects on RA. Ligusticum chuanxiong Hort
has been demonstrated to have anti-inflammatory func-
tion [19]. Radix Astragali could reduce cell accumula-
tion, relieve the swelling and arthritic index of joints,
and down-regulate the serum concentrations of TNFα
and IL-1β in adjuvant-induced arthritis [22]. Lonicera ja-
ponica Thunb was proved to have anti-inflammatory,
anti-oxidative and anti-carcinogenic effects [21, 32]. The
extract of Radix Gentianae Macrophyllae possesses sig-
nificant antinociceptive and anti-inflammatory activities
[20]. Tail Radix Angelicae Sinensis is characterized by
hematopoietic, antioxidant, and immunoregulatory ac-
tivities [23]. Rehmannia glutinosa Libosch and Manis tet-
radactyla were found to play effective roles in bone
metabolism. Rehmannia glutinosa Libosch has been
proved to stimulate the proliferation and activity of oste-
oblasts and to inhibit the generation and resorptive ac-
tivity of osteoclasts [24].
The HPLC-ESI/MSn analysis was used to identify the
predominant chemical constituents in XFHM. Negative
and positive base peak mass spectrums were measured to
obtain information about their chemical constituents. The
21 chemical constituents shown in Table 1 were identified
Fig. 3 Percentages of CD3+ T cells in peripheral blood cells (PB) and splenocytes. a Histogram of flow cytometry (FCAS): a normal group, b model
group, c LEF group and d XFHM group. b The results are presented in the bar charts. Data are presented as the means ± S.D. (n = 6). **P < 0.01
indicates model group vs. normal group; #P < 0.05 and ##P < 0.01 indicate treatment groups vs. model group
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from full composition granules of XFHM. Several lines of
evidence indicate that Veratric acid [33], Loganic acid [34],
Paeoniflorin [35], Loganin [36] and apiin [37] have anti-
inflammatory and immune-regulatory activities. Gentiopi-
croside [38], Astragaloside IV [39], Acteoside [40] and
Prime-O-glucosylcimifugin [41] exert anti-inflammatory ef-
fects by inhibiting the activation of NF-κB and other signal-
ing pathways. Isoimperatorin can inhibit TNFα-induced
expression of VCAM-1 by up-regulating the production of
PPAR-γ and translating signals to ERK1/2, PI3K, and PKC
[42]. Chlorogenic acid [17] and Caffeic acid [43] have in-
hibitory effects on the inflammatory proliferation of syno-
viocytes. Wogonin can down-regulate the production of
MMP-3, acting directly on articular chondrocytes [44].
Wogonoside inhibits LPS-induced angiogenesis both in
vitro and in vivo [45]. Naringenin can manipulate the
immunostimulatory properties of DCs and thus represents
a potential therapeutic for the treatment of RA [46]. In
addition, Formononetin can increase allergic responses by
enhancing IL-4 production in T cells [47]. Taken together,
these findings suggest that functions of the constituents of
XFHM synergistically contributed to the therapeutic effects
for RA treatment.
In the pathogenesis of RA, inflammatory cells including
monocytes and leukocytes infiltrate into the joint tissues,
along with the proliferation of synovial lining cells, then
leading to pannus formation which covers the surface of
articular cartilage and bone. Pannus produces various pro-
inflammatory cytokines and chemokines, leading to the
destruction of cartilage and bone [48]. The present results
of Safranin O and immunohistochemical staining showed
that XFHM could relieve the articular cartilage injury
characterized by proteoglycan loss, reduced the level of
pro-inflammatory cytokines IL-1β and IL-17, inhibit the
inflammatory infiltration in the synovium, and thus repair
the destruction of cartilage and bone.
Antigen-presenting cells present arthritis-associated an-
tigens to T cells, thereby initiating RA pathogenesis. Acti-
vated T cells infiltrate into the synovial membrane,
combine with autocrine pro-inflammatory cytokines, and
then induce inflammation in the synovium. B cells, also
known as antigen-presenting cells in the pathogenesis of
RA, can secrete auto-antibodies, thus further stimulating
the production of pro-inflammatory cytokines. The activa-
tion of T and B cells increases the production of cytokines
and chemokines, contributing to a feedback loop for the
interaction of T cells, macrophages and B cells [5]. NK
cells have been reported to have protective and pathogenic
roles in RA [49]. Interactions of NK cells with other im-
mune cells boost the release of pro-inflammatory cyto-
kines, contributing to inflammation of the synovium in
RA. Our results indicated that XFHM can modulate the
Fig. 4 Percentages of CD3−CD19+ B cells in PB and splenocytes. a Histogram of FCAS: a normal group, b model group, c LEF group and d XFHM
group. b The results are presented in the bar charts. Data are presented as the means ± S.D. (n = 6). **P < 0.01 indicates model group vs. normal
group; ##P < 0.01 indicate treatment groups vs. model group
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differentiation of T and B cells, inhibiting the inflamma-
tory progress in the synovium of RA.
Within the microenvironment of inflamed articular cartil-
age in RA, IL-1β, TNFα, IFNγ, IL-6 and IL-17 are the dom-
inant pro-inflammatory cytokines. These cytokines have
pleiotropic effects [48]. Myeloid origin cells, including mac-
rophages and dendritic cells, produce most of the TNFα,
IL-1β and IL-6. IFNγ and IL-17 produced by T helper 1
(Th1) and Th17cells respectively, are known as the defining
cytokines for these cells. These pro-inflammatory cytokines
Fig. 5 Percentages of CD3−NK1.1+ NK cells in PBMCs and splenocytes. a Histogram of FCAS: a normal group, b model group, c LEF group and
d XFHM group. b The results are presented in the bar charts. Data are presented as the means ± S.D. (n = 6). **P < 0.01 indicates model group vs.
normal group; #P < 0.05 and ##P < 0.01 indicate treatment groups vs. model group
Fig. 6 The levels of pro-inflammatory and anti-inflammatory cytokines in serum detected by inflammation antibody array assay. Data are presented as the
means ± S.D. (n= 6). *P< 0.05 and **P< 0.01 indicate model group vs. normal group; #P< 0.05 and ##P< 0.01 indicate treatment groups vs. model group
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interact synergistically, participating in the proliferation and
differentiation of pathogenic cells, inflammatory cell migra-
tion, pannus formation, and the process of destruction of
cartilage and bone [50, 51]. IL-4, IL-10 and IL-13, as the
classic anti-inflammatory cytokines, can decrease the
production of inflammatory cytokines, and thus inhibit
synovial inflammation and bone damage [52, 53]. In the
present study, we found that XFHM decreased the
production of pro-inflammatory cytokines that promote
autoimmune pathology and that it displayed immunosup-
pressive activities. Strangely, it had no positive regulatory
effect on the production of anti-inflammatory cytokines. In
TCM, combinations of plant species and minerals, called
formulae, are often prescribed based on clinical experience.
In formulae, multiple components could interact with mul-
tiple targets and exert synergistic therapeutic efficacy. The
regulatory mechanism of XFHM on the production of pro-
inflammatory and anti-inflammatory cytokines needs to be
researched deeply.
NF-κB, a transcription factor, is involved in inflamma-
tion, cell survival, proliferation and differentiation. In-
creased NF-κB activity contributes to the chronic
inflammatory characteristic of RA. NF-κB protein normally
exists as homo- or hetero-dimers. The homo- or hetero-
Fig. 7 Effect of XFHM on inhibiting activation of the NF-κB signaling pathway. a and b IKKα/β and NF-κB p50 were detected in whole spleen tissue
lysates by western-blot analysis. The quantified results are presented in a bar chart. GAPDH was used as an internal control. Data are presented as
means ± S.D. (n = 6). **P < 0.01 indicates model group vs. normal group; #P < 0.01 and ##P < 0.01 indicate treatment groups vs. model group
Fig. 8 Effect of XFHM on inhibiting activation of the JAK/STAT signaling pathway. a and b gp130, JAK1 and STAT3 were detected in whole
spleen tissue lysates by western-blot analysis. The quantified results are indicated by a bar chart. GAPDH was used as an internal control. GAPDH
was used as an internal control. Data are presented as the means ± S.D. (n = 6). **P < 0.01 indicates model group vs. normal group; #P < 0.01 and
##P < 0.01 indicate treatment groups vs. model group
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dimers combine with an NF-κB inhibitor (IκB) to form a
cytoplasmic complex that inhibits its entry into the nu-
cleus. IKKα/β mediates the phosphorylation of IκB. IκB
phosphorylation prompts its proteasome-mediated degrad-
ation through ubiquitination. NF-κB dimers are released
and free to migrate into the nucleus. The released NF-κB
dimers bind to promoter regions and induce the expres-
sion of target genes. Previous investigations have detected
NF-κB activation in RA synovium, and the expression of
p50 and p65 has been observed in synovial intimal lining
cells by immunohistochemical analysis [54, 55]. Further-
more, the JAK/STAT signaling pathway, known as the IL-6
pathway, offers novel potential therapeutic opportunities
that aim to prevent bone destruction in RA [56]. IL-6 acti-
vates the JAK/STAT signaling cascade through binding to
gp130, which triggers the phosphorylation of JAK/STAT in
primary rheumatoid synoviocytes. Phosphorylated STAT3
proteins are dimerized, consequently translocating into the
nucleus, and then regulate target gene transcription [57].
In this study, we discovered that XFHM could regulate the
secretion of pro-inflammatory cytokines by inhibiting the
activation of the NF-κB and JAK/STAT signaling pathway
induced by TNFα, IL-1β or IL-6.
LEF is a classic DMARD for RA treatment. It inhibits the
enzymatic activity of dihydroorotate dehydrogenase and
has anti-proliferative effects. The activation of T cells de-
pends on signal transduction of the dihydroorotate de-
hydrogenase pathway particularly. LEF also inhibits the
activity of pro-inflammatory cytokines such as TNF and IL-
1, relieves inflammation, delays the progress of joint and
cartilage destruction, and thus improves the quality of life
of RA patients [58]. In this study, we also obtained signifi-
cant anti-inflammatory effects and inhibitory action on
bone destruction through LEF treatment for CIA. However,
a recent study indicated that LEF had myelosuppressive
and hepatotoxic potential in a rat model of RA [59]. Ad-
verse drug reactions to LEF, such as pruritus, loss of appe-
tite, weak, dizziness, diarrhea and erythra, also occur
frequently in clinics. Multi-herbal formulas based on trad-
itional medicine have been scientifically verified as a com-
plementary and alternative therapy for the treatment of
various diseases. Formulae composed of a mixture of nat-
ural products have the presumed ability to target multiple
sites. In our study, XFHM was verified as an effective medi-
cine for RA treatment. It can also avoid the myelosuppres-
sive, hepatotoxic potential and other adverse reactions that
occur due to chemical drugs including LEF. In the present
study, the results indicated that the effects of anti-
inflammation and inhibition of bone and cartilage destruc-
tion of XFHM were equal to or exceeded those of LEF.
Conclusions
In summary, our results indicate that XFHM can suppress
the inflammatory swelling in joints, inhibit inflammatory
infiltration in synovium and relieve cartilage and bone de-
struction in CIA mice. The main mechanisms likely involve
to the modulation of T, B and NK cell differentiation, a
decrease in inflammatory hyperplasia of synovium, and
pro-inflammatory cytokine secretion by suppressing the ac-
tivation of NF-κB and the JAK/STAT signaling pathway.
The use of XFHM should be an optional complementary
and alternative therapy for RA treatment.
Additional file
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